Valneva SE (VALN)
| Market Cap | 2.20B |
| Revenue (ttm) | 134.54M |
| Net Income (ttm) | -78.53M |
| Shares Out | 48.94M |
| EPS (ttm) | -1.60 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 70,359 |
| Open | 44.30 |
| Previous Close | 44.84 |
| Day's Range | 43.68 - 45.39 |
| 52-Week Range | 24.16 - 59.15 |
| Beta | 0.91 |
| Analysts | n/a |
| Price Target | n/a |
| Est. Earnings Date | Nov 18, 2021 |
About VALN
Valneva is a specialty vaccine company focused on the development and commercialization of prophylactic vaccines for infectious diseases with significant unmet medical need. We take a highly specialized and targeted approach to vaccine development, beginning with the identification of deadly and debilitating infectious diseases that lack a prophylactic vaccine solution and for which there are limited therapeutic treatment options. We then apply our deep understanding of vaccine science, including our expertise across multiple vaccine modalities...
Financial Performance
In 2020, Valneva's revenue was 110.32 million, a decrease of -12.58% compared to the previous year's 126.20 million. Losses were -64.39 million, 3,592.3% more than in 2019.
Financial numbers in millions EURFinancial StatementsNews
Valneva (VALN) Reports Positive Data From COVID Vaccine Study
Valneva's (VALN) shares surge after its COVID vaccine demonstrates superiority over AstraZeneca's COVID vaccine in a phase III study.
These 2 Nasdaq Biotechs Are Making Huge Premarket Moves Monday
The Nasdaq looks poised to open slightly lower after a strong week.
Why Are Valneva's Shares Trading Higher Monday Premarket?
Valneva SE's (NASDAQ: VALN) COVID-19 vaccine elicits a robust immune response with far fewer side effects than the Oxford/AstraZeneca plc's (NASDAQ: AZN) jab, according to Phase 3 trial results. Valneva...
Valneva Reports Positive Phase 3 Results for Inactivated, Adjuvanted COVID-19 Vaccine Candidate VLA2001
Saint Herblain ( France), October 18 , 2021 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced positive topline results from the Phase 3 pivotal trial Cov-Com...
Valneva Announces the Cancellation of Ordinary Shares Held by the Company following Termination of its Liquidity Agre...
Saint- Herb lain (France) , October 4 , 2021 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that the Management Board has decided, during a meeting today,...
Valneva to Present and Hold Investor Meetings at the Guggenheim Vaccines and Infectious Disease Conference
Saint- Herb lain (France) , September 30 , 2 021 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that its senior management will present and participate in...
Valneva, Pfizer Lyme Disease Vaccine Candidate Drops-Off After 18 Months
Valneva SE (NASDAQ: VALN) and Pfizer Inc (NYSE: PFE) have announced more positive Phase 2 results, including the booster response, for their Lyme disease vaccine candidate VLA15. The 246-subject study i...
Valneva, Pfizer's Phase 2 Data Suggests Booster Strategy For Lyme Disease Vaccine Candidate
Valneva SE (NASDAQ: VALN) and Pfizer Inc (NYSE: PFE) have announced more positive Phase 2 results, including the booster response, for their Lyme disease vaccine candidate VLA15. The 246-subject study i...
Valneva and Pfizer Report Further Positive Phase 2 Results, Including Booster Response, for Lyme Disease Vaccine Cand...
Saint- Herblain ( France) and New York (United States) , September 28 , 2021 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, and Pfizer Inc. (NYSE: PFE), today announced f...
Valneva Continues To Expand COVID-19 Vaccine Candidate Trials
Valneva SE (NASDAQ: VALN) has commenced recruitment of adolescents in its pivotal Phase 3 trial for its inactivated COVID-19 vaccine candidate VLA2001 in the U.K. Topline results from the trial, dubbed ...
Valneva Continues Expansion of Clinical Trials of its Inactivated COVID-19 Vaccine Candidate VLA2001
Saint- Herb lain (France ) , September 23 , 2021 – Valneva SE, (Nasdaq: VALN; Euronext Paris: VLA) a specialty vaccine company, today announced that it has commenced recruitment of adolescents in its pi...
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Valneva SE - VALN
New York, New York--(Newsfile Corp. - September 21, 2021) - Pomerantz LLP is investigating claims on behalf of investors of Valneva SE ("Valneva" or the "Company") (NASDAQ: VALN). Such investors are adv...
UK cancels Covid vaccine deal with French firm Valneva
Government serves notice to terminate contract over allegations of a ‘breach of obligations'
Valneva: U.S. DoD Exercises First Year Option on IXIARO® Supply Contract
Saint Herblain ( France), September 3 , 2021 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA) a specialty vaccine company, today announced that the U.S. Department of Defense (DoD) has exercised the fir...
Valneva to Participate in Goldman Sachs Eleventh Annual Biotech Symposium
Saint- Herb lain (France) , September 1 , 2 021 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that its senior management will participate in 1-on-1 meeti...
Valneva (VALN) Begins Submission for COVID-19 Vaccine in UK
Valneva (VALN) starts rolling submission for the initial approval of its COVID-19 vaccine candidate, VLA2001, in the United Kingdom.
Valneva Commences Rolling Submission to MHRA for its Inactivated, Adjuvanted COVID-19 Vaccine
Saint-Herblain (France), August 23, 2021 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company focused on prophylactic vaccines for infectious diseases, today commenced rolling s...
Valneva Initiates Further Phase 3 Clinical Trial for its COVID-19 Vaccine Candidate
Saint-Herblain (France), August 11th, 2021 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company focused on the development and commercialization of prophylactic vaccines for inf...
Valneva Reports H1 2021 Financial Results and Provides Business Update
Key R&D Milestones Achieved
Valneva Announces Positive Phase 3 Pivotal Results for its Single-Shot Chikungunya Vaccine Candidate
Saint Herblain ( France), August 5 , 2021 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company focused on the development and commercialization of prophylactic vaccines for infe...
Valneva Appoints Peter Buhler as Chief Financial Officer
Saint- Herblain (France), July 29 , 2021 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company focused on the development and commercialization of prophylactic vaccines for infec...
Valneva and Pfizer Complete Recruitment for Phase 2 Trial of Lyme Disease Vaccine Candidate
Saint- Herblain ( France) and New York, NY , July 19 , 2021 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company focused on the development and commercialization of prophylactic...
Valneva's Chikungunya Vaccine Candidate Gets FDA Breakthrough Tag
The FDA grants Breakthrough Therapy Designation to Valneva SE's (NASDAQ: VALN) single-shot chikungunya vaccine candidate, VLA1553. This new U.S. milestone comes in addition to the FDA Fast Track designa...
Valneva Strengthens Management Team; Appoints Vincent Dequenne as SVP Operations and Joshua Drumm as VP Investor Rela...
Saint- Herblain (France), July 6 , 2021 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company focused on the development and commercialization of prophylactic vaccines for infect...